Blood-Brain Barrier

Blood–brain barrier Protective barriers of the brain.jpg Blood and CSF brain barriers Details System Neuroimmune system Identifiers Acronym(s) BBB The blood–brain barrier (BBB) is a highly selective semipermeable membrane barrier that separates the circulating blood from the brain and extracellular fluid in the central nervous system (CNS). The blood–brain barrier is formed by brain endothelial cells and it allows the passage of water, some gases, and lipid-soluble molecules by passive diffusion, as well as the selective transport of molecules such as glucose and amino acids that are crucial to neural function. Furthermore, it prevents the entry of lipophilic potential neurotoxins by way of an active transport mechanism mediated by P-glycoprotein. Astrocytes have been claimed to be necessary to create the blood–brain barrier. A few regions in the brain, including the circumventricular organs, do not have a blood–brain barrier.

Blood-Brain Barrier Products Targets

Products for Blood-Brain Barrier - Page 2

  1. Cat.No. Product Name Information/Activity
  2. BCC6229 LDV FITC 1207610-07-8 LDV FITC chemical structure
  3. BCC6332 Leukadherin 1 Leukadherin-1 is a specific agonist of complement receptor 3 (CR3) and the leukocyte surface αMβ2 integrin CD11b/CD18. Leukadherin 1 chemical structure
  4. BCC3943 MNS MNS is a potent and selective inhibitor of Src and Syk tyrosine kinases. MNS chemical structure
  5. BCC7458 OGT 2115 OGT 2115 is a potent, cell-permeable and orally active heparanase inhibitor with an IC50 of 0.4 μM. OGT 2115 has anti-angiogenic properties (IC50 of 1 μM). OGT 2115 also inhibits heparan sulfate degradation activity. OGT 2115 chemical structure
  6. BCC6275 P11 848644-86-0 P11 chemical structure
  7. BCC6105 PM 102 1234564-95-4 PM 102 chemical structure
  8. BCC7694 RGDS peptide Arg-Gly-Asp-Ser is an integrin binding sequence that inhibits integrin receptor function, decreases systemic inflammation via inhibition of collagen-triggered activation of leukocytes and attenuates expression of inflammatory cytokines, iNOS and MMP-9. RGDS peptide chemical structure
  9. BCC7894 RWJ 50271 RWJ 50271 is an selective inhibitor of lymphocyte function-associated antigen-1/intercellular adhesion molecule-1(LFA-1/ICAM-1) interaction with an IC50 of 5.0 μM (HL60 cells). RWJ 50271 chemical structure
  10. BCC6216 TC-I 15 916734-43-5 TC-I 15 chemical structure
  11. BCC6080 TCS 2314 TCS 2314 (compound 3) is orally active and selective very late antigen-4 (VLA-4, α4β1, CD49d/CD29) antagonist with an IC50 of 4.4 nM. TCS 2314 chemical structure

Items 11 to 20 of 119 total